Journal
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Volume 24, Issue 6, Pages 468-472Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1078155217715903
Keywords
Microbiome; checkpoint inhibitors; ipilimumab; nivolumab; pembrolizumab; immune surveillance
Categories
Funding
- National Institutes of Health [R01GM106024, R33CA173264, UL1TR000039, P20GM103625, P20GM103429]
Ask authors/readers for more resources
The field of gut microbiota is of growing interest, especially in the recent discoveries of its interaction with host immune responses, which when disrupted, can further alter immunity. It also plays a role in cancer development, its microenvironment and response to anticancer therapeutics. Several recently published experimental studies had explored the efficacy of modifying microbiota to enhance the response of checkpoint inhibitors, suggesting its beneficial function in cancer management and potential to be targeted as a therapeutic agent to enhance efficacy of checkpoint inhibitors. Here we review available evidence, mechanisms and hypotheses of its use to enhance cancer response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available